{
  "docId": "019de070-dce8-70ee-8639-85282f075771",
  "docSlug": "622e4280fc41e900213786c9a95190a7",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 40,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to summarize key business drivers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-dce8-70ee-8639-85282f075771/37",
  "deckHref": "/decks/019de070-dce8-70ee-8639-85282f075771",
  "deckJsonHref": "/decks/019de070-dce8-70ee-8639-85282f075771.json",
  "deckAnchorHref": "/decks/019de070-dce8-70ee-8639-85282f075771#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.258
      },
      "kind": "list",
      "text": "Improving financials: Nine blockbuster medicines; Returned to durable revenue and earnings growth; Focus on operating leverage and cash flow",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b610205-51c6-4479-b23d-de2764f81283",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.258
      },
      "kind": "list",
      "text": "Global presence: Balanced specialty and primary-care franchises; Leading emerging markets presence with R&D base",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dde8c1e-6c8d-42db-8ad1-3914d532c76d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.258
      },
      "kind": "list",
      "text": "Strong pipeline: 22 Phase III medicines and significant lifecycle projects; Advancing early- and mid-stage pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d15c5d-d4a8-4f20-be74-c9bd8169ab2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.745
      },
      "kind": "paragraph",
      "text": "Innovative medicines in Oncology, BioPharmaceuticals and rare diseases. Experienced and proven team",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea2a42c6-29ac-43a3-bff5-53acdae6fe69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.918
      },
      "kind": "source-note",
      "text": "1. In Q1 2021, speciality-care medicines (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 51% of total revenue 2. Last four quarters 3. Cardiovascular, Renal & Metabolism and Respiratory & Immunology 4. Subject to the Alexion acquisition.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf6d28bc-80f7-4a4f-83d6-8316ba701124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.41,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Pipeline-driven transformation",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f34b9bd1-d6c1-4372-83bf-b3e6c2bb1d26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.39,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "AstraZeneca in summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee45634d-8bb7-424c-b55a-29ab8fe3b5e1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "18f8cdfa-91bd-4484-8b3c-3aea1ae41b20",
      "evidence": "Improving financials: Nine blockbuster medicines; Returned to durable revenue and earnings growth; Focus on operating leverage and cash flow Strong pipeline: 22 Phase III medicines and significant lifecycle projects; Advancing early- and mid-stage pipeline Global presence: Balanced specialty and primary-care franchises; Leading emerging markets presence with R&D base",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}